The Anti-Proliferative Effect of PI3K/mTOR and ERK Inhibition in Monolayer and Three-Dimensional Ovarian Cancer Cell Models

Simple item page
dc.contributor.authorDunn, E
dc.contributor.authorChitcholtan, K
dc.contributor.authorSykes, P
dc.contributor.authorGarrill, Ashley
dc.date.accessioned2024-11-26T00:59:10Z
dc.date.available2024-11-26T00:59:10Z
dc.date.issued2022
dc.description.abstractMost ovarian cancer patients are diagnosed with advanced stage disease, which becomes unresponsive to chemotherapeutic treatments. The PI3K/AKT/mTOR and the RAS/RAF/MEK/ERK kinase signaling pathways are attractive targets for potential therapeutic inhibitors, due to the high frequency of mutations to PTEN, PIK3CA, KRAS and BRAF in several ovarian cancer subtypes. However, monotherapies targeting one of these pathways have shown modest effects in clinical trials. This limited efficacy of the agents could be due to upregulation and increased signaling via the adjacent alternative pathway. In this study, the efficacy of combined PI3K/mTOR (BEZ235) and ERK inhibition (SCH772984) was investigated in four human ovarian cancer cell lines, grown as monolayer and three-dimensional cell aggregates. The inhibitor combination reduced cellular proliferation in a synergistic manner in OV-90 and OVCAR8 monolayers and in OV-90, OVCAR5 and SKOV3 aggregates. Sensitivity to the inhibitors was reduced in three-dimensional cell aggregates in comparison to monolayers. OV-90 cells cultured in large spheroids were sensitive to the inhibitors and displayed a robust synergistic antiproliferative response to the inhibitor combination. In contrast, OVCAR8 spheroids were resistant to the inhibitors. These findings suggest that combined PI3K/mTOR and ERK inhibition could be a useful strategy for overcoming treatment resistance in ovarian cancer and warrants further preclinical investigation. Additionally, in some cell lines the use of different three-dimensional models can influence cell line sensitivity to PI3K/mTOR and RAS/RAF/MEK/ERK pathway inhibitors.
dc.identifier.citationDunn E, Chitcholtan K, Sykes P, Garrill A (2022). The Anti-Proliferative Effect of PI3K/mTOR and ERK Inhibition in Monolayer and Three-Dimensional Ovarian Cancer Cell Models. Cancers. 14(2). 395-.
dc.identifier.doihttp://doi.org/10.3390/cancers14020395
dc.identifier.issn2072-6694
dc.identifier.urihttps://hdl.handle.net/10092/107301
dc.languageeng
dc.publisherMDPI AG
dc.rightsAll rights reserved unless otherwise stated
dc.rights.urihttp://hdl.handle.net/10092/17651
dc.subjectBEZ235
dc.subjectSCH772984
dc.subjectcombination chemotherapy
dc.subjectdactolisib
dc.subjectovarian cancer
dc.subjectspheroids
dc.subjectthree-dimensional model
dc.subject.anzsrc1112 Oncology and Carcinogenesis
dc.subject.anzsrc32 - Biomedical and clinical sciences::3211 - Oncology and carcinogenesis
dc.titleThe Anti-Proliferative Effect of PI3K/mTOR and ERK Inhibition in Monolayer and Three-Dimensional Ovarian Cancer Cell Models
dc.typeJournal Article
uc.collegeFaculty of Science
uc.departmentSchool of Biological Sciences
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
The Anti-Proliferative Effect of PI3KmTOR and ERK Inhibition in Monolayer and Three-Dimensional Ovarian Cancer Cell Models.pdf
Size:
3.35 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
3.17 KB
Format:
Plain Text
Description:
Download
Collections
Science: Journal Articles